This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Beth Israel Deaconess Medical Center, Inc., Cornell University, Pfizer Corporation. Active years: 2016-2025.
Company Filing History:
2 out of 536 
1 out of 2,948 
1 out of 4,486 
Years Active: 2016-2025
Title: Brooke M Emerling: Innovator in Antibody Therapeutics
Introduction
Brooke M Emerling is a prominent inventor based in San Diego, CA. She has made significant contributions to the field of antibody therapeutics, holding 2 patents that focus on innovative approaches to cancer treatment.
Latest Patents
Her latest patents include the development of CDCP1 antibodies and antibody drug conjugates. This patent provides materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy. Another notable invention involves the modulation of phosphatidylinositol-5-phosphate-4-kinase activity. This invention features methods for identifying compounds that modulate the activity of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K). Inhibitors of PI5P4K can be utilized in the treatment or prevention of cell proliferation disorders, such as the prevention of tumor cell growth in p53 mutated cancers.
Career Highlights
Throughout her career, Emerling has worked with esteemed organizations, including Beth Israel Deaconess Medical Center and Pfizer Corporation. Her work has significantly advanced the understanding and treatment of various cancers.
Collaborations
Emerling has collaborated with notable scientists, including Lewis C Cantley and Atsuo Sasaki, further enhancing her research and contributions to the field.
Conclusion
Brooke M Emerling is a trailblazer in the realm of antibody therapeutics, with her innovative patents paving the way for new cancer treatments. Her work continues to inspire advancements in medical research and therapeutic development.